Rectal Dosage Formulation Development Service
The rectal route of administration offers a unique physiological landscape that remains underutilized in modern drug development. CD BioGlyco provides specialized rectal dosage formulation development services, enabling biopharmaceutical companies to bypass common oral delivery obstacles such as gastric degradation and high hepatic first-pass metabolism. By leveraging the venous drainage of the lower rectum, which bypasses the portal system, we enhance the systemic bioavailability of sensitive molecules, including oligonucleotides and small-molecule drugs.
At CD BioGlyco, we recognize that rectal drug delivery (RDD) requires a sophisticated understanding of rectal anatomy and fluid dynamics. Our development programs focus on optimizing residence time, controlling drug release kinetics, and ensuring patient comfort. Whether the goal is local treatment for inflammatory bowel disease (IBD) or rapid systemic uptake for emergency therapeutics, our scientific team designs customized rectal platforms that ensure high molecular stability and predictable pharmacokinetic profiles.
We utilize advanced materials science to overcome the historical challenges associated with rectal administration:
We utilize poloxamer-based systems that remain liquid at room temperature for ease of administration but undergo a phase transition to a robust gel at body temperature, preventing leakage and ensuring prolonged mucosal contact.
Utilizing carbopol and cellulose derivatives to design formulations that adhere specifically to the rectal mucosa. This technology extends the residence time of the drug, which is critical for local therapies and oligonucleotides requiring extended absorption windows.
Engineering solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) within the suppository base to protect fragile payloads from enzymatic degradation and enhance lymphatic uptake.
Designing pressurized or non-pressurized foam systems that provide superior spreadability compared to traditional suppositories, ensuring the drug reaches the proximal segments of the rectum and sigmoid colon for conditions like ulcerative colitis.
The rectal dosage formulation development service covers a diverse array of therapeutic modalities. We specialize in the formulation of both traditional small molecules and complex biologicals. Our scope includes the development of thermosensitive rectal gels, which provide a significant advantage over traditional liquid enemas by reducing the "urge to defecate" and improving drug retention. We also offer expertise in multi-chamber rectal systems, allowing for the simultaneous delivery of incompatible APIs or the co-administration of a drug with a localized buffer or penetration enhancer.
Our capabilities extend to:
By integrating analytical excellence with innovative delivery tech, we ensure that the rectal route becomes a powerful strategic asset in your drug development portfolio.
We conduct a comprehensive pre-formulation assessment to model the drug's behavior within the rectal environment. This involves determining critical parameters such as the partition coefficient (Log P) and solubility in biorelevant rectal fluid media. By simulating physiological conditions, including pH, fluid volume, and surface tension, we can accurately predict the drug's release and permeation profile. This foundational modeling is crucial for making a data-driven selection of the ideal delivery format, whether suppository, enema, or foam, to ensure optimal bioavailability for the intended therapeutic action.
A critical step involves the strategic selection and screening of suppository bases. We conduct a comparative evaluation of traditional fatty bases (e.g., Witepsol, Suppocire) versus water-soluble or dispersible bases (e.g., polyethylene glycols - PEG, gelatin). Using advanced techniques like differential scanning calorimetry (DSC) and hot stage microscopy (HSM), we meticulously assess the thermal behavior and physical compatibility between the active pharmaceutical ingredient (API) and the base. This ensures the final base choice provides the desired melting point, drug release kinetics, and, most importantly, avoids any potential chemical interactions that could compromise API stability.
Building on the base selection, our team develops and iterates multiple formulation prototypes. We engineer these prototypes by strategically integrating functional excipients such as mucoadhesive polymers (e.g., chitosan, polycarbophil) to enhance local retention, or penetration enhancers (e.g., sodium caprate, medium-chain glycerides) to improve mucosal absorption. The selection and concentration of these agents are optimized based on the specific pharmacokinetic and pharmacodynamic requirements of the target therapeutic index, aiming to maximize efficacy while ensuring local tolerability.
Each prototype undergoes a rigorous battery of mechanical and in vitro performance tests. This includes analyzing critical physical properties such as liquefaction/disintegration time, softening point, mechanical strength, and uniformity of content. Furthermore, we employ specialized dissolution apparatus to generate biologically relevant drug release profiles under conditions that mimic the rectal environment. This data is essential for confirming that the dosage form will perform as intended in vivo.
The finalized prototype formulation progresses to scale-up and stability studies. The manufacturing process is optimized for pilot-scale production, ensuring critical quality attributes are maintained. Subsequently, the scaled-up batches are placed on accelerated and long-term stability studies under ICH guidelines to monitor the chemical and physical stability of the product over time. This crucial phase verifies that the lab-scale success can be reliably translated into a stable, commercially viable product.
Journal: Frontiers in pharmacology
DOI: 10.3389/fphar.2019.01196
IF: 4.8
Published: 2019
Results: In this comprehensive review, Hua et al. systematically examine the rectal route as a practical alternative for drug delivery when oral administration is infeasible due to clinical or pharmaceutical constraints. The article highlights the rectum's relatively stable environment, low enzymatic activity, and potential to bypass hepatic first-pass metabolism, making it suitable for both local and systemic drug actions. It delves into key physiological factors, such as anatomy, pH, and fluid volume, that influence absorption, while comparing rectal delivery to other gastrointestinal routes. The review covers conventional formulations like suppositories and enemas, alongside innovative systems including nanoparticles and mucoadhesive gels. Despite advancements, translational challenges persist, such as patient acceptability and formulation retention, underscoring the need for further research to harness the full potential of rectal drug delivery in personalized medicine.
Emergency Pediatrics
Developing rapid-acting rectal gels for the treatment of status epilepticus in children where intravenous access is difficult and oral administration is impossible due to seizures.
Inflammatory Bowel Disease (IBD)
Engineering targeted foams and mucoadhesive gels for ulcerative colitis and Crohn's disease, ensuring local high-concentration delivery with minimal systemic exposure.
RNA-Based Therapeutics
Developing specialized rectal carriers for siRNAs and ASOs aimed at treating local colorectal genetic disorders or achieving systemic uptake through the rectal lymphatic system.
Migraine and Acute Pain
Engineering fast-absorption rectal platforms that provide rapid relief when oral medications are ineffective due to gastric stasis often associated with severe migraine attacks.
Protection for Biologics
We specialize in protecting nucleic acids and peptides within the rectal environment. Our lipid-based rectal carriers can protect payloads from the limited enzymatic activity in the rectum, outperforming oral delivery.
Superior Spreadability with Foams
Our foam formulations provide a much larger surface area coverage compared to suppositories. This ensures that the therapeutic agent reaches higher into the sigmoid colon, which is essential for effective local treatment of IBD.
Minimized GI Side Effects
By bypassing the stomach and upper intestine, our rectal development services help clients avoid common gastric irritations associated with oral drugs, providing a safer alternative with sensitive GI tracts.
High Stability and Long Shelf Life
We optimize the anhydrous nature of fatty suppository bases to provide superior chemical stability for moisture-sensitive drugs, ensuring a robust shelf life even in challenging storage conditions.
We saw a 40% increase in the bioavailability of our lead peptide when CD BioGlyco transitioned it from oral to their lipid-based rectal platform. Their technical team is top-tier.
— By Dr. R. Vogel, Head of Clinical Pharmacology
The 'mini-suppository' design CD BioGlyco created was a huge win for our geriatric portfolio. It improved patient compliance due to the ease of use and comfort.
— By Director of Product Strategy
CD BioGlyco's ability to stabilize siRNAs in a rectal matrix is unique. They provided a robust formulation that protected our nucleic acid payload from degradation while ensuring mucosal uptake.
— By Principal Scientist, Cardiovascular Unit
High-purity small interfering RNA production with custom modification options.
Precision synthesis of microRNA mimics and inhibitors for regulatory research.
Advanced antisense oligonucleotide synthesis for targeted gene silencing.
Developing high-affinity nucleic acid ligands for diagnostic and therapeutic use.
CD BioGlyco is a leading specialist in rectal dosage formulation development, turning the unique physiological advantages of the rectal route into a tangible success for our clients. By combining advanced polymer science, lipid nanotechnology, and deep anatomical knowledge, we ensure that your drug candidates, whether small molecules or oligonucleotides, achieve optimal stability and therapeutic performance. To discuss how our rectal delivery expertise can add value to your drug development program, or to request a detailed technical proposal, please contact us.
Reference
